Jump to top menu Jump to main menu Jump to content
Department

Hematology

Fundamental, translational and applied research into normal and malignant hematopoiesis, stem cell transplantation, developmental diagnostics and therapeutics, and hemostasis and thrombosis.

About our department

Our research

At the department of Hematology we are dedicated to improving the diagnosis and treatment of patients with hematological diseases. We perform basic and translational research to generate insight into the pathobiology of hematological diseases, and translate these findings into novel treatments for our patients.

In addition, we direct a wide variety of clinical studies, closely linked to our preclinical programs. These clinical studies deal with the development of molecular diagnostics, advancement of allogeneic stem cell transplantation, circumvention of drug-resistance to chemotherapy as well as a broad range of clinical phase I to phase III trials for a variety of hematological diseases.

For more information on specific research lines please select a principle investigator from the list below or select a particular hematological disease in the list of research lines.

For more information on clinical care for patients with hematological diseases please see our clinical homepage.

Follow this link to see all our studies.

Principal Investigators


Research lines

Projects

News, events and awards

Our news

 

Virtual Hematology Lectures Fall 2022

Time: Mondays 16:00 hrs / 04.00 PM CET
Location: Zoom 
Contact: Prof Dr Ruud Delwel, h.delwel@erasmusmc.nl, Mrs. Tessa Mannee, t.mannee@erasmusmc.nl
Duration: 1 hour
Cost: Free of charge & no registration required
Webinar ID: 859 4865 5311 
Zoom link: https://us06web.zoom.us/j/85948655311

07 Februari 2022

Louis M. Staudt, National Cancer Institute, Bethesda, U.S.A.

Rational development of targeted therapies for genetic subtypes of aggressive lymphoma
Host: Ivo Touw, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

14 February 2022

Delfim Duarte, i3S, Porto, Portugal 

Microenvironment and iron in acute myeloid leukemia
Host: Emma de Pater, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

21 Februari 2022

Dan Landau, Weill Cornell Medical College/ New York Genome Center, New York, U.S.A.

Charting clonal hematopoietic differentiation topologies with single-cell multi-omics
Host: Mathijs Sanders, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

28 Februari 2022

Charles Mullighan, St. Jude Comprehensive Cancer Center, Memphis, U.S.A.

Lineage ambiguous leukemia
Host: Ruud Delwel, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

07 March 2022

Stuart H. Orkin, Harvard Medical School/ HHMI, Boston, U.S.A.

Reactivation of fetal hemoglobin for therapy of hemoglobin disorders
Host: Peter Valk, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

14 March 2022

Peter van Galen, Brigham and Women’s Hospital/ Harvard Medical School/ Broad Institute, Boston, U.S.A.

Tracing leukemia evolution and immune cell interactions using single-cell multi-omics
Host: Marc Raaijmakers, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

21 March 2022

Heiko Bruns, University Hospital Erlangen, Erlangen, Germany

Function and significance of tumor-associated macrophages in lymphoma
Host: Tom Cupedo, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

28 March 2022

Peter Campbell, Wellcome Sanger Institute, Hinxton, U.K.

Somatic mutations in normal tissues
Host: Mathijs Sanders, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

04 April 2022

Lisa Russell, Newcastle University, Newcastle upon Tyne, U.K.

Super-enhancer activation of proto-oncogenes in acute lymphoblastic leukaemia: from discovery to treatment
Host: Ruud Delwel, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

11 April 2022

Cécile Denis, INSERM, Le Kremlin-Bicetre, France

New developments in von Willebrand factor research
Host: Frank Leebeek, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

25 April 2022

Wilbur Lam, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, U.S.A.

Development and clinical translation of engineered microsystems in hematology
Host: Ruben Bierings, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

02 May 2022

John W. Weisel, University of Pennsylvania, Philadephia, U.S.A.

Mechanisms of blood clot contraction and its significance for hemostasis and thrombosis
Host: Moniek de Maat, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

09 May 2022

Mihai Netea, Radboud University Medical Center, Nijmegen, The Netherlands

Trained immunity: a memory for innate host defense
Host: Marc Raaijmakers, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

16 May 2022

Jolanta Grembecka, University of Michigan, Ann Arbor, U.S.A.

Targeted inhibition of epigenetic modifiers in leukemia
Host: Ruud Delwel, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

23 May 2022

Jens Lohr, Dana-Farber Cancer Institute, Boston, U.S.A.

Promiscuous lineage identity and clinical implications in patients with multiple myeloma
Host: Tom Cupedo, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

30 May 2022

Siddhartha Jaiswal, Stanford University School of Medicine, Stanford, U.S.A.

Clonal hematopoiesis in human aging and disease
Host: Peter Valk, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

20 June 2022

Roni Shouval, Memorial Sloan Kettering Cancer Center, New York, U.S.A.

Hallmarks of response and toxicity to CAR T-cell therapy
Host: Emma de Pater, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

27 June 2022

Ivo Touw, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Molecular pathogenesis of congenital neutropenia
Host: Marc Raaijmakers, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Grant

Grant Department Hematology ErasmusMC for single cell analyses in hematologic malignancies

The Hematology department has received a grant of €100.000 from the Stichting Leukemie (www.leukemie.nl) for single cell analysis of hematological malignancies, in particular acute myeloid leukemia (AML).

Peter Valk Award Department Hematology

AML is an example of a heterogeneous group of hematologic malignancies with a variable response to therapy. The heterogeneity of AML is illustrated by the different (combinations of) mutations that occur with AML. Based on these mutations the prognosis of the AML patient can be estimated. However, despite the fact that prognostics in AML has greatly improved in recent decades, there is still much to be learned.

Residual disease during therapy of a haematological malignancy is a good predictor for getting recurrence of disease. We have recently demonstrated that the use of next generation sequencing in residual disease detection greatly improves the quantitative prediction of a recurrence (M. Jongen et al., NEJM 378, 2018).

The analyses in the above study were performed on the bulk of the AML cells. Analysis of DNA abnormalities at the level of a single cell will ultimately be necessary to determine which cells within a heterogeneous population of cells are critically important for the return of the AML. The grant from the Stichting Leukemie will be used to purchase equipment for the analysis of residual disease in AML at the single cell level.

Education